VISEN Pharmaceuticals (VISEN Pharma-B) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 30 April 2026, showing no movement in either authorised or issued share capital during the month.

• Authorised capital remained at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to USD 50,000.

• Issued share capital closed the month unchanged at 113.93 million ordinary shares; the company held no treasury shares.

• VISEN Pharma confirmed that its public float continues to satisfy the Main Board’s minimum 25% requirement.

• No share options, warrants, convertible securities or other equity instruments were issued, exercised, or redeemed in April.

• Under the Post-IPO Share Award Scheme adopted on 16 November 2022, no new shares were issued or transferred in the month, leaving capacity for up to 2.40 million shares to be granted in future.

The company’s disclosure indicates a stable capital structure, with all regulatory confirmations signed by Executive Director Lu An-Bang on 6 May 2026.